Want to see BLTE full AI Analyst Report?
EarningsQ2 2026 Earnings Report
BLTE Q2 2026 EPS Results
Actual EPS-$0.70
Consensus EPS-$0.78
Beat/MissBeat by +$0.08
One Year Ago EPS-$0.50
BLTE Q2 2026 Revenue Results
Actual Revenue$0.00
Expected Revenue$0.00
Beat/MissMet expectations
YoY Revenue Growth―
Earnings Announcement Details
QuarterQ2 2026
Date08/13/2026
TimeBefore Open
Conference CallThursday, August 13, 2026
BLTE Upcoming Earnings
Belite Bio, Inc. ADR's next earnings date is estimated for November 17, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
BLTE Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed substantial positive progress: NDA acceptance with priority review and a clear PDUFA date, supportive Phase 3 QAF data, strong cash balance ($780M), a pediatric program, and high patient compliance. Counterbalancing these positives are materially higher R&D and SG&A expenses, a widening net loss, a confidential one‑time royalty payment, limited disclosure on manufacturing inspection status, and a delayed GA interim readout. The positives (regulatory momentum, strong efficacy signal, and financial runway) outweigh the operational and expense-related concerns.Company Guidance
NDA Accepted with Priority Review and PDUFA Date
FDA accepted the tinlarebant NDA with priority review and set a PDUFA date of 2027-02-12, signaling regulatory momentum toward potential US approval.
Phase 3 Dragon Secondary Endpoint — QAF Results
Phase 3 Dragon secondary endpoint data presented: tinlarebant-treated subjects showed ~2% decrease in quantitative autofluorescence (QAF) at Month 25 vs baseline, while placebo subjects showed ~20% increase over the same period — a result that aligns with the drug's mechanism and supports disease-modifying potential.
Strong Cash Position and Runway
Company ended the quarter with $780 million in cash, cash equivalents and U.S. Treasury bills and states it is well funded to commercialize tinlarebant following potential approval and to continue advancing the pipeline.
Pediatric Development Plan
Initiating a PIP pediatric study in London to investigate tinlarebant in ages 3–11 to inform regulatory submissions for patients younger than 12, indicating proactive planning for label expansion into pediatrics.
High Trial Compliance
Reported patient compliance in the Stargardt study in excess of 90% at 24 months, supporting real-world feasibility of the dosing regimen.
Global Data Dissemination and Community Engagement
Presented Phase 3 Dragon results at four medical conferences across four countries and reported active engagement with medical and patient communities, emphasizing strong stakeholder interest and advocacy.
Priority Review Voucher Expected
Company expects to receive a Priority Review Voucher upon approval due to Rare Pediatric Disease designation; decision to sell or retain the voucher remains under consideration (potential value to balance future funding or strategic options).
Japan Regulatory Pathway in Parallel
Japan filing activity is underway with Sakigake designation; company expects Japan submission/approval activity to follow the FDA approval (estimated ~3 months after US approval), and Dragon 2 is primarily intended for PMDA review.
BLTE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed